Biocon Biologics secures deal with Janssen to launch biosimilar Bmab 1200

Quick Summary:

The reference brand, Stelara, had worldwide sales of $10.85 billion in 2023.

Stelara (Ustekinumab) is a monoclonal antibody medication that prevents the abnormal regulation of interleukin IL-12/23-associated immune diseases.

Biosimilar, according to one definition, is similar to another biological medicine that has already been approved, called the reference medicine.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: IndiaCanadaIrelandJapanUnited KingdomUnited States

Topics: Biosimilar Bmab1200 Janssen Biocon Biologics Biological medicines Medicines

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-08-29 @ 11:54:18 (4 days ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 304 words

Reading Time: 2 minutes read

Sentences: 13 lines

Sentence Length: 24 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 22293391

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 309 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 3 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions